Lpath, Inc.

Scott R Pancoast

Marina Safonov

Roger A Sabbadini

William A Garland

Genevieve Hansen

Glenn L Stoller

James Leigh Hsu

The present invention relates to compositions that comprise an anti-S1P monoclonal antibody, antibody fragment, or derivative in a carrier, particularly a buffered, hypertonic aqueous solution, as well as to kits containing such compositions, and methods for using such compositions for treatment of diseases and conditions associated with S1P.

Pharmaceutical compositions for binding sphingosine-1-phosphate

The present invention relates to methods that involve administration of an anti-S1 P antibody or antibody fragment or derivative to a subject having or suspected of having an ocular disease or condition, including one involving choroidal neovascularization, in order to achieve a desired effect. Such effects include reducing the size of a choroidal neovascularization lesion in the eye, decreasing or resolving retinal pigment epithelial detachment, decreasing central retinal lesion thickness, and preserving or improving visual acuity. Pharmaceutical compositions comprising an anti-S1 P antibody for ocular administration are also provided. The compositions and methods are particularly useful for treating subjects having age-related macular degeneration, particularly exudative or wet age-related macular degeneration.

Anti-S1P antibody treatment of patients with ocular disease

Growing community of inventors

Rancho Santa Fe, CA, United States of America

Scott R Pancoast